In the new study, long-term anticoagulation therapy with dabigatran (Pradaxa, Boehringer Ingelheim) inhibited thrombin and abnormal deposition of fibrin in a mouse model of AD. After receiving dabigatran for 1 year, the mice had no memory loss, and there was no reduction in cerebral circulation. Dabigatran also reduced typical AD symptoms, including cerebral inflammation, blood vessel injury, and amyloid protein plaques. - https://www.medscape.com/viewarticle/919772?nlid=132012_2051&src=WNL_mdplsnews_191011_mscpedit_psyc&uac=298760FG&spon=12&impID=2127014&faf=1